



# Phase I, Wave III List of Drugs Impacted by Prior Authorization Reinstatement

---

August 16, 2022

## What Providers Need to Know

In anticipation of the reinstatement of prior authorization (PA) requirements for new start medications for beneficiaries 22 years of age and older, providers have requested that the Department of Health Care Services (DHCS) publish a list of drugs that fall under the Standard Therapeutic Classes (STCs) for Phase I, Wave III, and subsequent phases and waves.

DHCS is pleased to support providers and has leveraged the existing [Medi-Cal Rx Approved National Drug Code \(NDC\) List](#) to identify each drug that has a PA requirement. Specifically, an additional column ("PA Status") has been added to indicate if a PA requirement is in effect as of January 1, 2022 ("AOO"); Phase I, Wave III ("P1W3"); or not in effect ("N/A"). This list will be updated monthly with the appropriate phase/wave until completion of the reinstatement process.

To enable filtered views, the Excel file will also include an additional set of tabs that display, by phase/wave, the drugs for which a PA requirement has been reinstated. Each tab will provide the STC description, NDC, and label name.

## What Providers Need to Do

Review the alert titled [Update: Implementation of Phase I, Wave III – Reinstatement of Prior Authorizations for 11 Drug Classes](#) to understand changes announced for Phase I, Wave III.

Review the alert titled [30-Day Countdown – Reinstatement of Prior Authorization Requirements for 11 Drug Classes](#) to identify the 11 drug classes slated for PA reinstatement on September 16, 2022.

Refer to the [Medi-Cal Rx Approved National Drug Code List](#) for information regarding medications requiring PAs.

## Questions?

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, please email Medi-Cal Rx Education & Outreach at [MediCalRxEducationOutreach@magellanhealth.com](mailto:MediCalRxEducationOutreach@magellanhealth.com).

ARCHIVED